A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386
in combination with pembrolizumab in participants with previously treated selected solid
tumors, and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination ...
Age: 18 years - 66+
Gender: All
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver
for hepatocellular cancer (HCC) detection in a surveillance population.
Age: 18 years - 66+
Gender: All
Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7
REPLACE is a phase III, multicenter, randomized, open-label trial to evaluate the efficacy
and safety of regorafenib and pembrolizumab (Rego-Pembro) versus transarterial
chemoembolization (TACE) or transarterial radioembolization (TARE) for the first-line
treatmen...
Age: 18 years - 66+
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing liver...
Age: 18 years - 66+
Gender: All
Study of SRF388 in Patients With Advanced Solid Tumors
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of SRF388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
Age: 18 years - 66+
Gender: All
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of
CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in
patients with solid tumors.
Age: 18 years - 66+
Gender: All
Case-Control Study of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma
Clinical guidelines (AASLD) recommend the use of abdominal ultrasound (US) for surveillance
testing for the early detection of Hepatocellular Carcinoma (HCC). The serum protein
biomarker alpha-fetoprotein (AFP) is commonly used to augment US but its use alone is not...
Age: 18 years - 66+
Gender: All
Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
This study will determine if the combination of regorafenib and pembrolizumab is safe and tolerated in patients with advanced liver cancer. In addition, the study will explore the anti-tumor activity of this combination as well as potentially identifying blood and tissu...
Age: 18 years - 66+
Gender: All
A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma
This is an open-label Phase 1b study designed to evaluate the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with hepatocellular carcinoma (HCC). The Expansion part of the study will evaluate objective response rate and duration ...
Age: 18 years - 66+
Gender: All